Merck & Co. (MRK)
(Delayed Data from NYSE)
$113.69 USD
+0.60 (0.53%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $113.60 -0.09 (-0.08%) 7:24 PM ET
4-Sell of 5 4
C Value C Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$113.69 USD
+0.60 (0.53%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $113.60 -0.09 (-0.08%) 7:24 PM ET
4-Sell of 5 4
C Value C Growth B Momentum B VGM
Zacks News
Company News for Aug 3, 2020
by Zacks Equity Research
Companies In The News Are: MRK, CVX, NOK, CHD.
Is a Beat in the Cards for Bristol-Myers' (BMY) Q2 Earnings?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports second-quarter 2020 results.
Merck (MRK) Beats on Q2 Earnings, Misses Sales, Ups View
by Zacks Equity Research
Merck (MRK) increases earnings and sales guidance for the year, which pushes shares up in pre-market trading.
Seattle Genetics (SGEN) Q2 Earnings Beat, Adcetris Aids Sales
by Zacks Equity Research
Seattle Genetics (SGEN) reports a narrower-than-expected loss and beats sales estimates in the second quarter of 2020.
More Earnings, Data Following Big Tech Q2 Blowout: XOM, MRK, CAT & More
by Mark Vickery
Markets finish out a busy week in the heart of Q2 earnings season with plenty of other leaders across a spectrum of industries, plus a few new economic reports.
Earnings & Economic Data Deluge
by Zacks Equity Research
Earnings & Economic Data Deluge
Merck (MRK) Q2 Earnings Beat Estimates
by Zacks Equity Research
Merck (MRK) delivered earnings and revenue surprises of 20.18% and -0.42%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
AstraZeneca (AZN) Q2 Earnings & Sales Beat, Increase Y/Y
by Zacks Equity Research
AstraZeneca (AZN) comes up with better-than expected Q2 results. It maintains its financial outlook for the year. Stock up.
How Much Will Coronavirus Hurt Merck's (MRK) Q2 Earnings? (Revised)
by Zacks Equity Research
Investor focus is likely to be on the impact of the coronavirus outbreak on Merck's(MRK) performance when it reports second-quarter earnings.
Pfizer (PFE) Q2 Earnings Top, Sales Hurt by Coronavirus, View Up
by Zacks Equity Research
Pfizer (PFE) beats estimates for earnings while missing the same for sales. It slightly raises its financial outlook for the year.
How Much Will Coronavirus Hurt Merck's (MRK) Q2 Earnings?
by Zacks Equity Research
Investor focus is likely to be on the impact of the coronavirus outbreak on Merck's (MRK) performance when it reports second-quarter earnings.
What Lies Ahead for Healthcare ETFs in Q2 Earnings?
by Sweta Killa
The healthcare sector is expected to witness substantial earnings decline of 6.9% in the second quarter, representing the second strongest sector this earnings season.
Earnings Preview: Merck (MRK) Q2 Earnings Expected to Decline
by Zacks Equity Research
Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for AstraZeneca (AZN) This Earnings Season?
by Zacks Equity Research
AstraZeneca's (AZN) second-quarter results are expected to reflect the impact of new drug sales. However, the impact of coronavirus pandemic remains to be seen.
3 Strong Dividend Stocks to Buy Now for Income & Coronavirus Growth
by Benjamin Rains
Let's dive into three stocks that are projected to grow during the pandemic that also provide solid income through dividends...
Will Pfizer's (PFE) BioPharma Unit Drive Its Q2 Earnings?
by Zacks Equity Research
In Pfizer's (PFE) Biopharma unit, oncology sales are likely to have risen in the second quarter, while in non-oncology, Eliquis alliance revenues are likely to have supported the top line.
Exelixis Starts Study on Cabometyx Combo in Kidney Cancer
by Zacks Equity Research
Exelixis (EXEL) initiates CONTACT-03, a global phase III pivotal study of Cabometyx (cabozantinib) in combination with Roche's Tecentriq.
Merck (MRK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Merck (MRK) closed at $79.41, marking a -0.58% move from the previous day.
Bristol-Myers' (BMY) CAR T Cell Therapy Gets EMA Validation
by Zacks Equity Research
Bristol-Myers' (BMY) MAA for its experimental candidate, liso-cel, gets validated by EMA.
Merck's NDA for Heart Failure Candidate Gets Priority Review
by Zacks Equity Research
FDA decision on Merck (MRK) and its Germany-based partner Bayer's vericiguat as a treatment to reduce heart failure is expected in January 2021.
AstraZeneca's Farxiga Gets Fast Track Tag for New Indication
by Zacks Equity Research
AstraZeneca's (AZN) Farxiga gets Fast Track status to reduce the risk of cardiovascular death or hospitalization for heart failure following a heart attack in adult patients.
Pharma Stock Roundup: J&J Q2 Earnings, FDA Approvals, Fast Track Tags & More
by Kinjel Shah
J&J (JNJ) beats Q2 estimates for earnings and sales. FDA grants fast track designation to Pfizer's (PFE) coronavirus vaccine candidates.
What To Expect From The Crazy Earnings Season Ahead
by Daniel Laboe
Are Netflix's disappointing results a foreshadowing of what is to come from the most parabolic tech stocks this earnings season?
Nabriva Soars on Agreement With Merck to Distribute Sivextro
by Zacks Equity Research
Nabriva (NBRV) signs a contract with the units of Merck for selling and distributing the latter's antibiotic Sivextro in the United States. Shares rise in pre-market trading.
J&J (JNJ) Beats on Q2 Earnings & Sales, Ups 2020 Guidance
by Zacks Equity Research
J&J (JNJ) beats second-quarter 2020 estimates for both earnings and sales. It increases its adjusted earnings and sales outlook for 2020.